BPC-157 + TB-500 Blend is a research compound studied for its role in recovery & healing research. This page covers mechanism of action, published studies, preclinical protocols, and analytical specifications.
Quick Reference: BPC-157 + TB-500 Blend
CAS Number
BPC-157: 137525-51-0 | TB-500: 107761-42-2
Molecular Formula
Combined — see individual compound specifications
Molecular Weight
BPC-157: 1419.5 g/mol | TB-500: 4963.5 g/mol
Sequence / Structure
10mg BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) + 10mg TB-500 (Tβ4 aa 17-23) per vial
Physical Form
Lyophilized powder blend
Purity (QSC)
≥99% each component (HPLC verified)
Storage
Store lyophilized blend at -20°C. Reconstituted: 4°C, use within 28 days.
Reconstitution
Add 2ml bacteriostatic water per 20mg blend vial. Inject slowly along vial wall. Swirl gently — do not shake.
Mechanism of Action
The BPC-157 + TB-500 Blend combines two of the most widely researched tissue repair peptides in a pre-mixed, co-lyophilized formulation. The rationale for their combined study is mechanistic complementarity — the two peptides act through distinct, non-overlapping biological pathways, with both pathways contributing to tissue repair across overlapping but distinct tissue contexts.
BPC-157’s Mechanisms (in the Blend): BPC-157 contributes multi-pathway repair signalling: nitric oxide (NO) synthesis upregulation for improved local blood flow; VEGF and EGF receptor upregulation for angiogenesis and cellular proliferation; direct tenocyte (tendon cell) stimulation for structural matrix repair; and gastrointestinal mucosal cytoprotection through prostaglandin-independent pathways.
TB-500’s Mechanisms (in the Blend): TB-500 contributes actin sequestration activity (G-actin binding to regulate cellular migration and division), independent angiogenesis promotion through VEGF upregulation and MMP modulation, anti-inflammatory cytokine modulation through NF-κB pathway downregulation, and potential stem cell recruitment in cardiac tissue models.
Mechanistic Complementarity: The key research rationale for combining the two peptides is the non-overlap of their primary mechanisms. BPC-157’s primary anabolic activity operates through NO and growth factor receptor pathways; TB-500’s primary activity operates through actin dynamics and independent angiogenic signalling. Research combining the two activates a broader repair signalling network than either compound alone, without redundancy at the receptor level.
Convenience and Dosing Consistency: Pre-blended formulations ensure consistent molar ratios between the two compounds in every vial — important for research protocols designed to study the combined effect at a fixed ratio rather than variable individual doses. QSC’s blend provides equal mass (10mg:10mg) of each component per vial.
Research Applications
Combined Tissue Repair Research: The primary application is studying whether simultaneous activation of BPC-157’s NO/growth factor pathways and TB-500’s actin/angiogenesis pathways produces additive or synergistic repair outcomes vs either compound administered alone — a head-to-head comparison requiring identical conditions across three groups.
Musculoskeletal Injury Models: Tendon transection, muscle laceration, and ligament sprain rodent models commonly use BPC-157, TB-500, and their blend in parallel experimental arms to characterise compound-specific and combined contributions to structural tissue healing.
Angiogenesis Research: Both compounds independently promote angiogenesis through different mechanisms. The blend is used to study whether dual-pathway angiogenesis stimulation produces superior vascularisation in ischemic tissue models vs single-compound administration.
Protocol Development: The blend simplifies multi-compound research protocols, enabling consistent co-administration without requiring separate reconstitution, dose calculation, and injection of two compounds — reducing procedural variability in animal research.
Key Published Research
Primary publications relevant to BPC-157 + TB-500 Blend research. Full citations available via PubMed. QSC does not endorse or make claims based on this research.
Sikiric et al. (2018)
“Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in GI Tract” — Current Pharmaceutical Design
Reviews BPC-157’s individual mechanisms, providing the half of the mechanistic rationale for the blend.
Gwyer et al. (2019)
“Gastric Pentadecapeptide BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing” — Cell and Tissue Research
Establishes BPC-157 musculoskeletal healing evidence base, directly relevant to combined research with TB-500.
Draw equal volumes for consistent molar ratio delivery across all experimental subjects
Frequently Asked Questions
What is the BPC-157 + TB-500 Blend?
A pre-mixed lyophilized blend containing equal masses of BPC-157 (10mg) and TB-500 (10mg) per vial, formulated for research studying the combined effects of two complementary tissue repair peptides. The blend enables consistent co-administration without separate reconstitution.
Why study BPC-157 and TB-500 together?
The two peptides act through distinct, non-overlapping mechanisms — BPC-157 through NO synthesis and growth factor receptor pathways; TB-500 through actin dynamics and independent angiogenesis signalling. Combined administration activates a broader tissue repair network than either compound alone, with research examining whether this produces additive or synergistic healing outcomes.
Is the blend the same as buying BPC-157 and TB-500 separately?
The pre-blended vial ensures a fixed 1:1 mass ratio in every reconstituted dose, which is harder to control when mixing separately reconstituted compounds. For research requiring consistent molar ratios across experiments, the blend provides better dosing consistency. For research requiring variable ratios, separate compounds are more appropriate.
How should the BPC-157 + TB-500 Blend be stored?
Lyophilized blend at -20°C. After reconstitution with 2ml bacteriostatic water, store at 4°C and use within 28 days.
What purity does each component carry?
Both BPC-157 and TB-500 in the blend are verified at ≥99% purity individually by HPLC and mass spectrometry before blending. A combined COA is available on the product page and via the Janoshik portal.
Research Use Only: All products sold on qsc-usa.com are intended strictly for laboratory research purposes only. They are not approved for human consumption, veterinary use, or any other application. Researchers are responsible for understanding and complying with local regulations in their jurisdiction.
Buy BPC-157 + TB-500 Blend — Domestic Shipping Available
